The mitochondrial SIR2 related protein 2 (SIR2RP2) impacts Leishmania donovani growth and infectivity
Nimisha Mittal1, Rohini Muthuswami2, Rentala Madhubala1
1School of Life Sciences, Jawaharlal Nehru University, New Delhi, India.
Background:
Leishmania donovani, a protozoan parasite is the major causative agent of visceral leishmaniasis. Increased toxicity and resistance to the existing repertoire of drugs has been reported. Hence, an urgent need exists for identifying newer drugs and drug targets. Previous reports have shown sirtuins (Silent Information Regulator) from kinetoplastids as promising drug targets. Leishmania species code for three SIR2 (Silent Information Regulator) related proteins. Here, we for the first time report the functional characterization of SIR2 related protein 2 (SIR2RP2) of L. donovani.
Methodology:
Recombinant L. donovani SIR2RP2 was expressed in E. coli and purified. The enzymatic functions of SIR2RP2 were determined. The subcellular localization of LdSIR2RP2 was done by constructing C-terminal GFP-tagged full-length LdSIR2RP2. Deletion mutants of LdSIR2RP2 were generated in Leishmania by double targeted gene replacement methodology. These null mutants were tested for their proliferation, virulence, cell cycle defects, mitochondrial functioning and sensitivity to known SIR2 inhibitors.
Conclusion:
Our data suggests that LdSIR2RP2 possesses NAD+-dependent ADP-ribosyltransferase activity. However, NAD+-dependent deacetylase and desuccinylase activities were not detected. The protein localises to the mitochondrion of the promastigotes. Gene deletion studies showed that ΔLdSIR2RP2 null mutants had restrictive growth phenotype associated with accumulation of cells in the G2/M phase and compromised mitochondrial functioning. The null mutants had attenuated infectivity. Deletion of LdSIR2RP2 resulted in increased sensitivity of the parasites to the known SIR2 inhibitors. The sirtuin inhibitors inhibited the ADP-ribosyltransferase activity of recombinant LdSIR2RP2. In conclusion, sirtuins could be used as potential new drug targets for visceral leishmaniasis.
Insights
Leishmania donovani SIR2RP2, an enzyme, exhibits ADP-ribosyltransferase activity and is crucial for parasite survival and infectivity. Targeting this sirtuin offers a promising strategy for developing new visceral leishmaniasis drugs.
Area of Science:
- Parasitology
- Molecular Biology
- Biochemistry
Background:
- Visceral leishmaniasis is caused by the protozoan parasite Leishmania donovani.
- Existing drugs for leishmaniasis face challenges of toxicity and drug resistance.
- Sirtuins (Silent Information Regulator proteins) are emerging as potential drug targets in kinetoplastids.
Purpose of the Study:
- To functionally characterize the Leishmania donovani SIR2 related protein 2 (LdSIR2RP2).
- To investigate the potential of LdSIR2RP2 as a drug target for visceral leishmaniasis.
Main Methods:
- Recombinant LdSIR2RP2 was expressed, purified, and its enzymatic activities assessed.
- Subcellular localization was determined using a GFP-tagged construct.
- Gene deletion mutants (null mutants) were created and analyzed for growth, virulence, cell cycle, mitochondrial function, and drug sensitivity.
Main Results:
- LdSIR2RP2 demonstrated NAD+-dependent ADP-ribosyltransferase activity but lacked deacetylase and desuccinylase functions.
- The protein was localized to the mitochondrion in Leishmania promastigotes.
- Null mutants exhibited restricted growth, G2/M phase cell cycle arrest, impaired mitochondrial function, and reduced infectivity.
- Deletion of LdSIR2RP2 increased parasite sensitivity to sirtuin inhibitors, which also inhibited the recombinant enzyme's activity.
Conclusions:
- LdSIR2RP2 is a functional enzyme with ADP-ribosyltransferase activity, essential for Leishmania donovani proliferation, mitochondrial function, and infectivity.
- Targeting LdSIR2RP2, a sirtuin, presents a viable strategy for developing novel therapeutic interventions against visceral leishmaniasis.
Related Concept Videos
ATP Synthase: Structure
Leishmaniasis
Antiprotozoal Agents


